참고문헌
- World Health Organization Report (2009) Global health risks: mortality and burden of disease attributable to selected major risks.
- Ross, J. S. and Ginsburg, G. S. (2002) Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug. Discov. Today 7, 859-864. https://doi.org/10.1016/S1359-6446(02)02405-4
- Nowell, P. and Hungerford, D. (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497.
- Lugo, T. G., Pendergast, A. M., Muller, A. J. and Witte, O. N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082. https://doi.org/10.1126/science.2408149
- Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J. and Lydon, N. B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566. https://doi.org/10.1038/nm0596-561
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182. https://doi.org/10.1126/science.3798106
- Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J. and Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for meta-static breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792. https://doi.org/10.1056/NEJM200103153441101
- Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J. and Press, M. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing meta-static breast cancer. J. Clin. Oncol. 20, 719-726. https://doi.org/10.1200/JCO.20.3.719
- Herbst. R. S., Fukuoka, M. and Baselga, J. (2004) Gefitinib-a novel targeted approach to treating cancer. Nat. Rev. Cancer 4, 956-965. https://doi.org/10.1038/nrc1506
- Ferrara, N. (2005) VEGF as a therapeutic target in cancer. Oncology 69 (Suppl. 3), 11-16. https://doi.org/10.1159/000088479
- Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y. and Mano, H. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566. https://doi.org/10.1038/nature05945
- Vo, T. T. and Letai, A. (2010) BH3-only proteins and their effects on cancer. Adv. Exp. Med. Biol. 687, 49-63. https://doi.org/10.1007/978-1-4419-6706-0_3
- Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C. and Ashworth, A. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921. https://doi.org/10.1038/nature03445
- Masamura, S., Santner, S. J., Heitjan, D. F. and Santen, R. J. (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 80, 2918-2925. https://doi.org/10.1210/jc.80.10.2918
- Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., Scott, M. A., Erber, W. N. and Green, A. R. ; Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061. https://doi.org/10.1016/S0140-6736(05)71142-9
- Liu, P., Cheng, H., Roberts, T. M. and Zhao, J. J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644. https://doi.org/10.1038/nrd2926
- Swaroop, A., Chew, E. Y., Bowes, Rickman, C. and Abecasis, G. R. (2009) Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu. Rev. Genomics Hum. Genet. 10, 19-43. https://doi.org/10.1146/annurev.genom.9.081307.164350
- Johnson, A. D. and O'Donnell, C. J. (2009) An open access database of genome-wide association results. BMC Med. Genet. 10, 6.
- Reddy, E. P., Reynold, R. K., Santos, E. and Barbacid, M. A. (1982) A point mutation is responsible for the acquisition of transforming properties of the T24 human bladder carcinoma oncogene. Nature 300, 149-152. https://doi.org/10.1038/300149a0
- Capon, D. J., Seeburg, P. H., McGrath, J. P., Hayflick, J. S., Edman, U., Levinson, A. D. and Goeddel, D. V. (1983) Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304, 507-513. https://doi.org/10.1038/304507a0
- Bos, J. L., Toksoz, D., Marshall, C. J., Verlaan-de Vries, M., Veeneman, G. H., van der Eb, A. J., van Boom, J. H., Janssen, J. W. and Steenvoorden, A. C. (1985) Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 315, 726-730. https://doi.org/10.1038/315726a0
- Lievre, A., Bachet, J. B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouche, O., Landi, B., Louvet, C., Andre, T., Bibeau, F., Diebold, M. D., Rougier, P., Ducreux, M., Tomasic, G., Emile, J. F., Penault-Llorca, F. and Laurent-Puig, P. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379. https://doi.org/10.1200/JCO.2007.12.5906
- Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D. and Chang, D. D. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with meta-static colorectal cancer. J. Clin. Oncol. 26, 1626-1634. https://doi.org/10.1200/JCO.2007.14.7116
- Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., Klein, P., Miller, V. A., Ostland, M. A., Ramies, D. A., Sebisanovic, D., Stinson, J. A., Zhang, Y. R., Seshagiri, S. and Hillan, K. J. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909. https://doi.org/10.1200/JCO.2005.02.857
- The Food and Drug Administration (2005) Drug-Diagnostic Co-Development Concept Paper (Draft-Not for Implementation).
- Holt, G. D. and Hart, G. W. (1986) The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J. Biol. Chem. 261, 8049-8057.
- Wang, Z., Gucek, M. and Hart, G. W. (2008) Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc. Natl. Acad. Sci. U.S.A. 105, 13793-13798. https://doi.org/10.1073/pnas.0806216105
- Maeda, Y. and Kinoshita, T. (2011) Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins. Prog. Lipid. Res. 50, 411-424. https://doi.org/10.1016/j.plipres.2011.05.002
- Yu, R. K., Tsai, Y. T., Ariga, T. and Yanagisawa, M. (2011) Structures, biosynthesis., functions of gangliosides-an overview. J. Oleo. Sci. 60, 537-544. https://doi.org/10.5650/jos.60.537
- Helenius, A. and Aebi, M. (2001) Intracellular functions of N-linked glycans. Science 291, 2364-2369. https://doi.org/10.1126/science.291.5512.2364
- Roth, J. (2002) Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. Chem. Rev. 102, 285-303. https://doi.org/10.1021/cr000423j
- Ko, J. H., Miyoshi, E., Noda, K., Ekuni, A., Kang, R., Ikeda, Y. and Taniguchi, N. (1999) Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines. J. Biol. Chem. 274, 22941-22948. https://doi.org/10.1074/jbc.274.33.22941
- Dall'Olio, F. and Chiricolo, M. (2001) Sialyltransferases in cancer. Glycoconj. J. 18, 841-850. https://doi.org/10.1023/A:1022288022969
- Cazet, A., Julien, S., Bobowski, M., Krzewinski-Recchi, M. A., Harduin-Lepers, A., Groux-Degroote, S. and Delannoy, P. (2010) Consequences of the expression of sialylated antigens in breast cancer. Carbohydr. Res. 345, 1377-1383. https://doi.org/10.1016/j.carres.2010.01.024
- Itzkowitz, S. H., Bloom, E. J., Kokal, W. A., Modin, G., Hakomori, S. and Kim, Y. S. (1990) Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66, 1960-1966. https://doi.org/10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X
- Ma, X. C., Terata, N., Kodama, M., Jancic, S., Hosokawa, Y. and Hattori, T. (1993) Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. Eur. J. Cancer 29A, 1820-1823.
- Burchell, J. M., Mungul, A. and Taylor-Papadimitriou, J. (2001) O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia 6, 355-364. https://doi.org/10.1023/A:1011331809881
- Kim, Y. S., Hwang, S. Y., Kang, H. Y., Sohn, H., Oh, S., Kim, J. Y., Yoo, J. S., Kim, Y. H., Kim, C. H., Jeon, J. H., Lee, J. M., Kang, H. A., Miyoshi, E., Taniguchi, N., Yoo, H. S. and Ko, J. H. (2008) Functional proteomics study reveals that N-Acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1. Mol. Cell. Proteomics. 7, 1-14. https://doi.org/10.1074/mcp.M700084-MCP200
- Ben-David, T., Sagi-Assif, O., Meshel, T., Lifshitz, V., Yron, I. and Witz, I. P. (2008) The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells. Immunol. Lett. 116, 218-224. https://doi.org/10.1016/j.imlet.2007.11.022
- Shirure, V. S., Henson, K. A., Schnaar, R. L., Nimrichter, L. and Burdick, M. M. (2011) Gangliosides expressed on breast cancer cells are E-selectin ligands. Biochem. Biophys. Res. Commun. 406, 423-429. https://doi.org/10.1016/j.bbrc.2011.02.061
- Chen, G., Howe, A. G., Xu, G., Frohlich, O., Klein, J. D. and Sands, J. M. (2011) Mature N-linked glycans facilitate UT-A1 urea transporter lipid raft compartmentalization. FASEB J. In press.
- Hollenstein, K., Dawson, R. J. and Locher, K. P. (2007) Structure and mechanism of ABC transporter proteins. Curr. Opin. Struct. Biol. 17, 412-418. https://doi.org/10.1016/j.sbi.2007.07.003
- Beretta, G. L., Benedetti, V., Cossa, G., Assaraf, Y. G., Bram, E., Gatti, L., Corna, E., Carenini, N., Colangelo, D., Howell, S. B., Zunino, F. and Perego, P. (2010) Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem. Pharmacol. 79, 1108-1117. https://doi.org/10.1016/j.bcp.2009.12.002
- Leffler, H., Carlsson, S., Hedlund, M., Qian, Y. and Poirier, F. (2004) Introduction to galectins. Glycoconj. J. 19, 433-440.
- Fred Brewer, C. (2002) Binding and cross-linking properties of galectins. Biochim. Biophys. Acta. 1572, 255-262. https://doi.org/10.1016/S0304-4165(02)00312-4
- Liu, F. T. and Rabinovich GA. (2005) Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29-41. https://doi.org/10.1038/nrc1527
- Camby, I., Le Mercier, M., Lefranc, F. and Kiss, R. (2006) Galectin-1: a small protein with major functions. Glycobiology 16, 137R-157. https://doi.org/10.1093/glycob/cwl025
- Garner, O. B. and Baum, L. G. (2008) Galectin-glycan lattices regulate cell-surface glycoprotein organization and signaling. Biochem. Soc. Trans. 36, 1472-1477. https://doi.org/10.1042/BST0361472
- Wu, A. M., Lisowska, E., Duk, M. and Yang, Z. (2009) Lectins as tools in glycoconjugate research. Glycoconj. J. 26, 899-913. https://doi.org/10.1007/s10719-008-9119-7
- Duverger, E., Frison, N., Roche, A. C. and Monsigny, M. (2003) Carbohydrate-lectin interactions assessed by surface plasmon resonance. Biochimie 85, 167-179. https://doi.org/10.1016/S0300-9084(03)00060-9
- Ahn, H. J., Kim, Y. S., Lee, C. H., Cho, E. W., Yoo, H. S., Kim, S. H. Ko, J. H. and Kim, S. J. (2011) Generation of antibodies recognizing an aberrant glycoform of human tissue inhibitor of metalloproteinase-1 (TIMP-1) using decoy immunization and phage display. J. Biotechnol. 151, 225-230. https://doi.org/10.1016/j.jbiotec.2010.12.004
- Yoshida-Moriguchi, T., Yu, L., Stalnaker, S. H., Davis, S., Kunz, S., Madson, M., Oldstone, M. B., Schachter, H., Wells, L. and Campbell, K. P. (2010) O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 327, 88-92. https://doi.org/10.1126/science.1180512
피인용 문헌
- Effect of posttranslational modifications on enzyme function and assembly vol.92, 2013, https://doi.org/10.1016/j.jprot.2013.03.025
- HSF1 and Sp1 Regulate FUT4 Gene Expression and Cell Proliferation in Breast Cancer Cells vol.115, pp.1, 2014, https://doi.org/10.1002/jcb.24645
- Semi-quantitative Measurement of a Specific Glycoform Using a DNA-tagged Antibody and Lectin Affinity Chromatography for Glyco-biomarker Development vol.14, pp.3, 2015, https://doi.org/10.1074/mcp.O114.043117
- Tumor-associated autoantibodies as diagnostic and prognostic biomarkers vol.45, pp.12, 2012, https://doi.org/10.5483/BMBRep.2012.45.12.236
- Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma vol.39, pp.2, 2017, https://doi.org/10.1177/1010428317691417
- Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progression vol.45, pp.11, 2012, https://doi.org/10.5483/BMBRep.2012.45.11.233
- Chondroitin sulfate-cell membrane effectors as regulators of growth factor-mediated vascular and cancer cell migration vol.1840, pp.8, 2014, https://doi.org/10.1016/j.bbagen.2014.01.009